Mobile Memory develops a cost-effective tool that utilizes artificial intelligence and vocal biomarker analysis to screen for early-onset Alzheimer's disease. This solution addresses the lack of accessible diagnostic methods, enabling timely intervention and treatment to slow disease progression.
Funding
Funding not disclosed
Founders
Product
Problem
Current diagnostic methods for early-onset Alzheimer's disease are often expensive and inaccessible, hindering timely intervention and treatment to slow disease progression. This lack of accessible screening tools delays detection, limiting opportunities to manage the disease effectively.
Solution
Mobile Memory offers an AI-powered tool that analyzes vocal biomarkers to screen for early-onset Alzheimer's disease. The technology aims to provide a cost-effective and accessible solution for early detection, enabling timely intervention and treatment. By leveraging vocal analysis, the tool seeks to democratize access to early diagnosis, empowering individuals to take proactive steps in managing their cognitive health and preserving their memories. The solution aims to disrupt the current paradigm of expensive and inaccessible diagnostic methods.
Target Audience
The primary target audience includes individuals concerned about their cognitive health, as well as healthcare providers seeking accessible and cost-effective screening tools for early-onset Alzheimer's disease.
Features
- AI-powered vocal biomarker analysis for early-onset Alzheimer's disease screening
- Cost-effective diagnostic tool
- Accessible screening method